Pre Exposure Prophylaxis News and Research

RSS

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP.

15 Sep 2012

Researchers, policymakers to gather at AIDS Vaccine 2012 conference in Boston

"With a completed trial in Thailand that offered evidence a vaccine could be developed to protect people from HIV, emerging science identifying antibodies against HIV, and a current trial testing a novel vaccine combination against the virus potentially producing more information in the next year, this is an exciting time to hold a conference, organizers of AIDS Vaccine 2012 say," the Center for Global Health Policy's "Science Speaks" blog reports.

7 Sep 2012

FDA approves Gilead’s Stribild to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

28 Aug 2012

International community must redouble efforts to ensure 'many' AIDS-free generations

A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia.

22 Aug 2012

GlobalPost examines debate surrounding PrEP

GlobalPost's "Global Pulse" blog examines questions surrounding the use of the antiretroviral Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at high risk, as studies released and panel discussions held last week at the XIX International AIDS Conference (AIDS 2012) "raised concerns about the drug's effect on the future of the AIDS fight."

31 Jul 2012

Letter to the editor: The role for pre-exposure prophylaxis in the fight against AIDS

This letter to Kaiser Health News responds to KHN's interview with Michael Weinstein, the president of the AIDS Healthcare Foundation.

27 Jul 2012

Recent release: Blogs discuss advancements in HIV preventative, therapeutic R&D

In this post in the Center for Global Health Policy's "Science Speaks" blog, IAVI President and CEO Margaret McGlynn, AVAC Executive Director Mitchell Warren and UNAIDS Executive Director Michel Sidibe highlight the release of a report from the HIV Vaccine & Microbicides Resource Tracking Working Group.

26 Jul 2012

Dapivirine Phase III trial now underway in Africa to treat HIV in women

A large clinical trial testing the long-term safety and effectiveness of a new approach for preventing HIV in women - a vaginal ring used once a month - is now underway in Africa, researchers announced today at the XIX International AIDS Conference (AIDS 2012).

25 Jul 2012

Implementing multifaceted global effort may help end global HIV/AIDS pandemic

Ending the global HIV/AIDS pandemic may be possible by implementing a multifaceted global effort that expands testing, treatment, and prevention programs, as well as meets the scientific challenges of developing an HIV vaccine and possibly a cure, according to a Viewpoint in the July 25 issue of JAMA, a theme issue on HIV/AIDS.

23 Jul 2012

Researchers identify high ARV drug exposure in hair samples of HIV uninfected infants

Researchers from the University of California, San Francisco (UCSF) and Makerere University in Uganda have used hair and blood samples from three-month old infants born to HIV-positive mothers to measure the uninfected babies' exposure—both in the womb and from breast-feeding—to antiretroviral medications their mothers were taking. The results, they said, are surprising.

23 Jul 2012

New WHO guidance recommends use of ARVs for HIV prevention

WHO has issued its first guidance to countries that are considering offering HIV medications, known as antiretrovirals (ARVs), to protect people who do not have the virus but who are at high risk of HIV infection.

21 Jul 2012

HIV in MSM increasing in countries of all incomes

A new Lancet Series published to coincide with the AIDS2012 meeting highlights a population where the HIV epidemic is growing in countries of all incomes: men who have sex with men (MSM). The first paper in the Series charts the epidemiology of HIV among MSM, and is by Professor Chris Beyrer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, and colleagues.

20 Jul 2012

NPR reports on Brazilian clinical trial of Truvada as prevention strategy

NPR's "Shots" blog reports on one of the drug trials considered by the FDA in its approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, which "was done at the Oswaldo Cruz Foundation Research Institute, also known as Fiocruz, in Rio de Janeiro."

19 Jul 2012

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection.

19 Jul 2012

Report shows high rates of HIV infections and deaths from AIDS among Black MSM

Today, the Black AIDS Institute released its latest report, Back of the Line: The State of AIDS Among Black Gay Men in America. The landmark report highlights alarming data that show disproportionately high rates of HIV infections and deaths from AIDS among Black MSM, why the disparities persist and are growing worse, and the urgent need for local and national leadership to immediately address the devastating health crisis.

19 Jul 2012

Advocates, policy experts respond to FDA approval of Truvada for HIV prevention

Though the FDA's Monday approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at risk of contracting the virus "was hailed by many as an important step in the fight against AIDS, concerns that people will incorrectly use the drug -- potentially spurring drug resistance -- led others to blast the agency for not laying down tougher rules," the Wall Street Journal's "Health Blog" writes.

18 Jul 2012

FDA approves Truvada as HIV prevention strategy for high-risk, uninfected individuals

The FDA on Monday announced the approval of the first drug for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, "which some are calling a landmark in the fight against AIDS," ABC News reports.

18 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

Studies show success, highlight challenges of PrEP strategy

The results of three clinical trials published on Wednesday in the New England Journal of Medicine show that the antiretroviral drug Truvada, a combination of tenofovir and emtracitabine, can be "highly effective at preventing infection in HIV-free individuals -- as long as those individuals take the drug every day as prescribed," CNN's "The Chart" reports (7/11).

13 Jul 2012